Rosuvastatin May Be Partially Effective in Moderating Residual Immune Activation on ART
October 1, 2014
Many HIV positive people never achieve a CD4 recovery to >500 cells/mm3 on ART even after many years on treatment. The role of residual immune activation in this response is unknown and as statins have anti-inflammatory effects their potential to modify immune activation may be important.
At AIDS 2014, Laurence Weiss, of the Université Paris Descartes, Paris, presented a poster from the CESAR-IMEA trial investigating whether rosuvastatin can decrease cellular and soluble markers of immune activation in patients receiving ART.1
In this open label, phase II trial, patients were enrolled who had >2 years ART, with CD4 counts <500 cells/mm3 and viral loads <40 copies/mL. C-reactive protein had to be <10 mg/mL with no indication for statin use. Rosuvastatin (20 mg, once-daily) was administered for 3 months, followed by 3 months follow up. The primary outcome was change in the proportion of CD38+ HLA-DR+CD8+ T lymphocytes after 12 weeks. Mean CD4 count at baseline was 319 cells/mm3 [IQR 284-442].
Of 50 patients who enrolled in the study, 43 reached study endpoints.
There was no significant change in the proportion of CD38+HLA-DR+CD8+ T cells throughout the follow-up. Despite this, the investigators reported a significant decline in the proportion of CD38+CD8+ T cells between baseline and week 12 (p=0.001) that was sustained until week 24. There were significant decreases in the percentage of Ki67+CD4+ T cells at week 12 (p=0.048), in HLA-DR+CD4+ T cells (p=0.044) and soluble CRP levels (p= 0.047). No changes were observed in the other soluble activation markers: IL-6, sCD14 and D-dimer.
The researchers concluded that rosuvastatin added to ART could result in sustained decreases in CD8 T cell activation. However, the lack of any decrease in the main marker of T cell activation, expression of CD38 and HLA-DR on CD8 T cells, is a major concern with this conclusion.
Although CD38 expression decreased on all CD8 T cells, this has questionable significance in terms of reducing T cell activation. CD38 can be constitutively expressed by various T cells in the absence of activation, for example naive T cells. Therefore it is not, on its own, a reliable marker of T cell activation and must be paired with other activation markers such as HLA-DR or markers of memory phenotype.
The reduction in the percentage of CD8 T cells expressing CD38, in the absence of a reduction in the percentage of CD8 T cells expressing both CD38 and HLA-DR together, calls into question the ability of rosuvastatin to reduce T cell activation in this study.
Despite this, the observed reduction in Ki67 in CD4 T cells is slightly more encouraging.
Weis L et al. A pilot study of the impact of rosuvastatin administration on residual chronic immune activation under antiretroviral therapy: the CESAR-IMEA trial. AIDS 2014: 20th International AIDS Conference. July 20-25, 2014. Melbourne. Abstract WEPE095.
Links to other websites are current at date of posting but not maintained.
This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.